High Singlet Oxygen Yields from a Polymer-Supported Photosensitizer via Superhydrophobicity and Control of Photosensitizer Morphology
- PMID: 40538498
- PMCID: PMC12176372
- DOI: 10.1016/j.apsusc.2025.162826
High Singlet Oxygen Yields from a Polymer-Supported Photosensitizer via Superhydrophobicity and Control of Photosensitizer Morphology
Abstract
Photosensitizers (PSs) dissolved in solvents generate reactive oxygen species, such as singlet oxygen (1O2), in high yields, especially when the PS is fully solvated and unaggregated. For many applications, such as water treatment, homogenous phase reactions are not practical because the PS will contaminate the solution and be difficult to recover and reuse. Immobilizing PSs on solid polymer supports is an emerging strategy for 1O2 applications, as it prevents the PS from entering the solution and thus enables PS reuse. However, 1O2 yields from polymer-supported PS surfaces are much lower than in solvated systems. In this paper, we employ novel approaches to modify surface topography and surface chemistry of the polymer support to significantly increase 1O2 yields. To fabricate the surfaces we deposit a fluorinated, water-insoluble porphyrin, 5,10,15,20-tetrakis(pentafluorophenyl)porphyrin (TFPP) onto polyethylene terephthalate (PET) and polydimethylsiloxane (PDMS) surfaces. We demonstrate that superhydrophobic surfaces exhibit a 2.9-fold higher yield of 1O2 compared to planar, wetted surfaces, even when the planar surfaces exhibit significant roughness from the addition of silica particles. Modifying the polymer surface chemistry to accelerate PS solution spreading decreases PS crystallite size thereby increasing PS surface area and further increasing 1O2 yields. Surface chemistry also affects PS aggregation; the PS forms J-aggregates on PET, but crystallizes in an unaggregated (non-overlapping) form on PDMS. Contrary to conventional assumptions, the PS aggregate state and higher loadings of the PS are not correlated with higher 1O2 yields, whereas reducing the size of PS crystallites significantly increases yields.
Conflict of interest statement
Conflicts of interest The authors declare the following competing financial interest(s): QianFeng Xu, Alexander Greer, and Alan Lyons are inventors of patents issued to the City University of New York and licensed to SingletO2 Therapeutics LLC. Dr. Xu is Chief Scientist at SingletO2 Therapeutics, and Drs. Greer and Lyons are co-founders and co-owners of SingletO2 Therapeutics LLC. H. B. Ihalagedara reports no conflicts of interest related to this study. Declaration of interests Alan M. Lyons and Alexander Greer reports a relationship with SingletO2 Therapeutics LLC that includes: equity or stocks. QianFeng Xu reports a relationship with SingletO2 Therapeutics LLC that includes: employment. Alan Lyons, Alexander Greer and QianFeng Xu has patent issued to SingletO2 Therapeutics LLC. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Maternal and neonatal outcomes of elective induction of labor.Evid Rep Technol Assess (Full Rep). 2009 Mar;(176):1-257. Evid Rep Technol Assess (Full Rep). 2009. PMID: 19408970 Free PMC article.
-
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948. Health Technol Assess. 2024. PMID: 39367772 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
References
-
- Gamelas SRD, Tomé JPC, Tomé AC, Lourenço LMO, Porphyrin-containing materials for photodegradation of organic pollutants in wastewaters: a review, Catal. Sci. Technol 14 (2024) 2352–2389. 10.1039/D4CY00092G. - DOI
-
- Valkov A, Raik K, Mualem-Sinai Y, Nakonechny F, Nisnevitch M, Water Disinfection by Immobilized Photosensitizers, Water 11 (2018) 26. 10.3390/w11010026. - DOI
-
- Alves E, Faustino MAF, Neves MGPMS, Cunha Â, Nadais H, Almeida A, Potential applications of porphyrins in photodynamic inactivation beyond the medical scope, J. Photochem. Photobiol. C Photochem. Rev 22 (2015) 34–57. 10.1016/j.jphotochemrev.2014.09.003. - DOI